MIRA
INFORM REPORT
|
Report Date : |
11.03.2011 |
IDENTIFICATION DETAILS
|
Name : |
f. hoffmann-la roche ag |
|
|
|
|
Registered Office : |
Grenzacherstrasse 124 4070 |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as on) : |
31.12.2010 |
|
|
|
|
Date of Incorporation : |
01.06.1989 |
|
|
|
|
Com. Reg. No.: |
270.3.000.406-0 / 81803 |
|
|
|
|
Legal Form : |
Company Limited by Shares |
|
|
|
|
Line of Business : |
Manufacture and sales of pharmaceutical and chemical products,
vitamins and Diagnostika |
RATING & COMMENTS
|
MIRA’s Rating : |
A |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
Maximum Credit Limit : |
CHF 15'000'000 |
|
Status : |
Good |
|
Payment Behaviour : |
Regular |
|
Litigation : |
Exists |
NOTES :
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – December 31, 2010
|
Country Name |
Previous Rating (30.09.2010) |
Current Rating (31.12.2010) |
|
|
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
Name and address
F. Hoffmann-La
Roche AG
Operating
address:
Grenzacherstrasse
124
4070
Switzerland/CH
Telephone: 061
6881111
Fax: 061
6919391
Web
site: http://www.roche.ch
E-mail: basel.webmaster@roche.com
VAT-No.: CHE-105.815.381
Profile
Established: 1896
History: 1896: Established from Fritz Hoffmann-La Roche
Line
of Business: Chemicals,
Pharmaceutics
Industry
Division: Manufacturing
Industry-code (NACE): 2053 Manufacture of essential oils
2014 Manufacture of other organic basic
chemicals
2120 Manufacture of pharmaceutical
preparations
2110 Manufacture of basic pharmaceutical
products
Import/Export: Export
Quality
certification: ISO 9001
ISO 14001
Banks: UBS Ltd
CS Credit
Suisse
Operational Figures
Coverage: Company
Figures: estimated
Employees: 7'775
Sales: CHF 7'800'000'000.--
Activity
The company comprises the manufacture and
sales of pharmaceutical and chemical products, vitamins and Diagnostika.
Real Estate
Information on property ownership was not
available.
Company Register
Company
No: 270.3.000.406-0 / 81803
Legal
form: Company limited
by shares
Registration: 01.06.1989
Legal
status: active
Responsible
Register: Handelsregister des Kantons
Basel-Stadt
Auditor: KPMG AG,
History: Date of Incorporation
Statutes: 31.05.1989
Date of
Statutes: 19.06.1997
Entry Deleted Name
active F.
Hoffmann-La Roche AG
active F.
Hoffmann-La Roche Ltd (Name translated)
active F.
Hoffmann-La Roche SA (Name translated)
Entry Deleted Legal domicile
active
Entry Deleted Address
active Grenzacherstrasse
124, 4058 Basel/BS, Switzerland/CH
Entry Deleted Capital
active Share
Capital CHF 150'000'000, paidup CHF 150'000'000
Entry Deleted Capital Structure
active 150'000
Registered shares of CHF 1'000.--
Entry Deleted Activity (original Language)
24.07.1997 Fabrikation
und Vertrieb pharmazeutischer und chemischer Produkte aller Art. Die
Gesellschaft kann Grundstücke und Immaterialgüterrechte erwerben und veräussern
sowie sich an anderen Unternehmen beteiligen.
Entry Deleted Remarks (original Language)
active Publishing
authority: SHAB.
active Merger:
Aktiven und Passiven der "Priorin AG", in Münchenstein, nach Massgabe
von Art. 748 OR. Da die übernehmende Gesellschaft Eigentümerin sämtlicher
Aktien der übernommenen Gesellschaft ist, findet keine Kapitalerhöhung statt.
active Contribution
in kind/Asset takeover: Betriebliche Aktiven und Passiven der "Roche
Holding AG", in
24.06.2008 Merger:
Übernahme der Aktiven und Passiven der Barimec Investment AG, in
20.04.2007 Note:
Redaktionelle Korrekturen von Personalien zur Bereinigung der Handelsregistereintragungen.
22.02.2007 Merger:
Übernahme der Aktiven und Passiven der "RoNexus Services AG", in
04.11.2005 Merger:
Übernahme der Aktiven und Passiven der 'Pharmexbio AG', in Zug
(CH-170.3.007.638-5), gemäss Fusionsvertrag vom 20.10.2005 und Bilanz per
31.08.2005. Aktiven von CHF 1'500'000.-- und Passiven (Fremdkapital) von CHF
115'336'000.--, d.h. ein Passivenüberschuss von CHF 113'836'000.--, gehen auf
die übernehmende Gesellschaft über. Gemäss Bestätigung des besonders befähigten
Revisors liegt ein Rangrücktritt im Umfang des Kapitalverlustes und der
Überschuldung vor. Da dieselbe Aktionärin sämtliche Aktien der an der Fusion
beteiligten Gesellschaften hält, findet weder eine Kapitalerhöhung noch eine
Aktienzuteilung statt.
06.12.2004 Merger:
Übernahme der Aktiven und Passiven der "NP Investments AG", in Glarus
(CH-160.3.001.126-7), gemäss Fusionsvertrag vom 29.11.2004 und Bilanz per
30.06.2004. Aktiven von CHF 3'022'859.22 und Passiven (Fremdkapital) von CHF
8'004'000.--, d.h. ein Passivenüberschuss von CHF 4'981'140.78, gehen auf die
übernehmende Gesellschaft über. Gemäss Bestätigung des besonders befähigten
Revisors liegen teils Rangrücktritte im Umfang des Kapitalverlustes und der
Überschuldung vor und teils verfügt die übernehmende Gesellschaft über frei
verwendbare Eigenmittel im erforderlichen Umfang. Da dieselbe Aktionärin
sämtliche Aktien der an der Fusion beteiligten Gesellschaften hält, findet
weder eine Kapitalerhöhung noch eine Aktienzuteilung statt.
06.12.2004 Merger:
Übernahme der Aktiven und Passiven der "Valorfides AG", in Chur
(CH-350.3.004.123-9), gemäss Fusionsvertrag vom 29.11.2004 und Bilanz per
30.06.2004. Aktiven von CHF 540'786'072.56 und Passiven (Fremdkapital) von CHF
349'172'234.61 gehen auf die übernehmende Gesellschaft über. Da dieselbe
Aktionärin sämtliche Aktien der an der Fusion beteiligten Gesellschaften hält,
findet weder eine Kapitalerhöhung noch eine Aktienzuteilung statt.
06.12.2004 Merger:
Übernahme der Aktiven und Passiven der "Roche Consumer Health Trading
AG", in
06.12.2004 Merger:
Übernahme der Aktiven und Passiven der "Roche Consumer Health Holding
AG", in
12.05.2003 Merger:
Die Gesellschaft übernimmt Aktiven von CHF 116'070.-- und Passiven von CHF
3'300.-- der "Roche Center for Medical Genomics, Ltd", in Basel, nach
Massgabe von Art. 748 OR. Da die übernehmende Gesellschaft Eigentümerin
sämtlicher Aktien der zu übernehmenden Gesellschaft ist, findet keine
Kapitalerhöhung statt.
24.07.1997 Reports:
Mitteilungen an die Aktionäre: Briefe.
17.12.1996 Board
of directors: Nicht eingetragene Prokuren Carol E. Horswil Harris und Donald L.
Kryzer erloschen. Streichung der statutarisch festgesetzten Anzahl der
Verwaltungsratsmitglieder, da nicht zur Eintragung gehörend.
Official Administration
Title Name
President Dr. Franz B.
Humer, Origin:
Chief
Executive Dr.
Severin Schwan, Origin:
Executive
Director Dr.
Gottlieb Keller, Origin:
Executive
Director Dr. Erich
Hunziker, Origin:
Executive
Director Urs
Lauffer, Origin:
Management
Title Name
Vice-Director Dr. Lutz Müller,
Origin:
Executive board
Title Name
Financial Data Roche Group
Consolidation: consolidated
Industry: Trade/Industry
Fiscal year end: 31.12.2010 31.12.2009 31.12.2008 31.12.2007 31.12.2006
Number of months: 12 12 12 12 12
Currency: mil.
CHF mil. CHF mil. CHF mil. CHF mil.
CHF
Statement norm: IAS IAS IAS IAS IAS
Balance Sheet
Intangible fixed
assets 12'855.0 14'266.0 15'474.0 13'181.0 11'383.0
Land and buildings 10'051.0 8'564.0 9'010.0 8'127.0 7'515.0
Other tangible
fixed assets 6'678.0 9'133.0 9'180.0 9'705.0 8'902.0
Tangible fixed
assets 16'729.0 17'697.0 18'190.0 17'832.0 16'417.0
Financial fixed
assets 428.0 481.0 940.0 1'333.0 2'159.0
other fixed assets 3'396.0 3'642.0 2'881.0 3'185.0 3'560.0
Fixed assets 33'408.0 36'086.0 37'485.0 35'531.0 33'519.0
Stocks 4'972.0 5'648.0 5'830.0 6'113.0 5'592.0
Trade accounts
receivable 9'403.0 10'461.0 9'755.0 9'804.0 8'960.0
Liquid assets 1'841.0 2'442.0 4'915.0 3'755.0 3'210.0
Securities 9'060.0 16'107.0 15'856.0 20'447.0 21'121.0
other trade
accounts 1'821.0 3'318.0 2'248.0 2'715.0 2'012.0
Accruals 515.0 503.0
other current
assets 13'237.0 22'370.0 23'019.0 26'917.0 26'343.0
Current assets 27'612.0 38'479.0 38'604.0 42'834.0 40'895.0
Total assets 61'020.0 74'565.0 76'089.0 78'365.0 74'414.0
Capital 160.0 160.0 160.0 160.0 160.0
Other shareholders
funds 9'309.0 7'206.0 44'319.0 45'323.0 39'284.0
Total shareholders
equity 9'469.0 7'366.0 44'479.0 45'483.0 39'444.0
Minority interests 2'193.0 2'048.0 9'343.0 7'960.0 7'370.0
long term debt
(financial debts) 27'857.0 36'143.0 2'972.0 3'834.0 6'199.0
Provisions 934.0 700.0 654.0 688.0 1'593.0
Other non current
liabilities 5'589.0 6'241.0 6'537.0 5'946.0 7'116.0
Non current
liabilities 34'380.0 43'084.0 10'163.0 10'468.0 14'908.0
short term debt
(financial debts) 2'201.0 6'273.0 1'117.0 3'032.0 2'044.0
Trade accounts
payable 2'068.0 1'299.0 1'053.0 1'188.0 2'213.0
Provisions 2'146.0 1'618.0 804.0 1'517.0 756.0
Accruals 4'938.0 7'917.0 5'684.0 5'645.0 3'834.0
other accounts
payable 3'625.0 4'960.0 3'446.0 3'072.0 3'845.0
other current
liabilities 10'709.0 14'495.0 9'934.0 10'234.0 8'435.0
Current
liabilities 14'978.0 22'067.0 12'104.0 14'454.0 12'692.0
Shareh. equity,
min. interests + liabilities 61'020.0 74'565.0 76'089.0 78'365.0 74'414.0
Profit and loss account
Net sales 47'473.0 49'051.0 45'617.0 46'113.0 43'507.0
Other operating
revenue 1'694.0 2'100.0 2'287.0 0.0 0.0
Operating revenue 49'167.0 51'151.0 47'904.0 46'113.0 43'507.0
Cost of goods sold 13'293.0 14'615.0 13'661.0 13'743.0 10'616.0
Gross profit 35'874.0 36'536.0 34'243.0 32'370.0 32'891.0
Other operating
expenses 22'388.0 24'259.0 20'319.0 17'902.0 21'161.0
Operating result 13'486.0 12'277.0 13'924.0 14'468.0 11'730.0
Interest revenues 64.0 179.0 698.0 1'072.0 788.0
other financial
revenues 656.0 613.0 426.0 733.0 470.0
Financial income 720.0 792.0 1'124.0 1'805.0 1'258.0
Interest expenses 2'506.0 1'733.0 214.0 281.0 315.0
other financial
expenses 489.0 1'104.0 673.0 690.0 88.0
Financial expenses 2'995.0 2'837.0 887.0 971.0 403.0
Financial result -2'275.0 -2'045.0 237.0 834.0 855.0
Result before
extraordinary items 11'211.0 10'232.0 14'161.0 15'302.0 12'585.0
Extraordinary
income 0.0 0.0 0.0 2.0 22.0
Extraordinary
expenses 0.0 0.0 0.0 0.0 0.0
Extraordinary
Result 0.0 0.0 0.0 2.0 22.0
Result before
taxes 11'211.0 10'232.0 14'161.0 15'304.0 12'607.0
Taxes 2'320.0 1'722.0 3'317.0 3'867.0 3'436.0
Result before
minority interests 8'891.0 8'510.0 10'844.0 11'437.0 9'171.0
minority interests 225.0 726.0 1'875.0 1'676.0 1'291.0
Result for the
financial year 8'666.0 7'784.0 8'969.0 9'761.0 7'880.0
Cash flow
Depreciation 1'933.0 1'981.0 2'645.0 2'536.0 2'542.0
Cash flow 10'824.0 10'491.0 13'489.0 13'973.0 11'713.0
Cash flow from operating
activities 14'342.0 16'877.0 12'177.0 11'728.0 10'329.0
Investments in
tangible fixed assets 2'671.0 2'984.0 3'139.0 3'519.0 3'561.0
Cash flow from
investing activities 3'534.0 -2'909.0 -1'722.0 -5'788.0 -7'450.0
Cash flow from
financing activities -18'434.0 -14'768.0 -9'442.0 -5'270.0 -3'715.0
Others -43.0 -1'673.0 147.0 -125.0 -182.0
Change in
liquidity -601.0 -2'473.0 1'160.0 545.0 -1'018.0
Liquidity at
beginning of the year 2'442.0 4'915.0 3'755.0 3'210.0 4'228.0
Liquidity at end
ot the year 1'841.0 2'442.0 4'915.0 3'755.0 3'210.0
Notes
Cost of employees 11'934.0 12'080.0 11'129.0 10'767.0 10'116.0
Research and
Development 9'050.0 9'874.0 8'845.0 8'385.0 6'589.0
Added value 27'584.0 26'026.0 28'149.0 28'888.0 25'580.0
Working Capital 12'307.0 14'810.0 14'532.0 14'729.0 12'339.0
Sales per Employee 0.6 0.6 0.6 0.6 0.6
Market
capitalisation 117'563.0 151'296.0 140'678.0 171'060.0 191'575.0
Gross cost land
and buildings 14'731.0 13'076.0 12'483.0 11'299.0 10'545.0
Gross cost other
tangible fixed assets 16'257.0 18'844.0 17'656.0 18'105.0 16'854.0
Gross cost total 30'988.0 31'920.0 30'139.0 29'404.0 27'399.0
Full time units at
year end 80'653 81'507 80'080 78'604 74'372
Employees inland 7'700 7'700 7'650 7'500 7'900
Employees abroad 72'953 73'807 72'430 71'104 66'472
Ultimate Parent Company
Name: Roche Holding AG
City/Country:
Owner/-s
No.
of Owner/-s: 1
Owner: The company is domestic
owned.
Class: 100%
Name: Roche Holding AG
City/Country:
Interest: 100.00% voting right,
100.00% capital interest
Investments
Class: 100%
Name: Piramed Limited
City/Country: Welwyn
Interest: 100.00% voting right,
100.00% capital interest (since 23.05.2008)
Class: 0-9%
Name: BEC AG
City/Country:
Interest: 5.00% voting right,
5.00% capital interest
Legal Actions
Control date Year No. Amount CHF Status
02.12.2009 2009 0
02.12.2009 2008 1 9'945.-- Legal actions
02.12.2009 2008 1 8'216.-- Opposition filed
02.12.2009 2007 1 2'500'000.-- Opposition filed
02.12.2009 2006 1 2'500'000.-- Opposition filed
An updated legal action check is only
available against proof of interest. e.g. a copy of an enquiry letter, and
order or invoice relating to the subject company.
Credit Information
Financial
Statements: The company does not
disclose any financial statements. Third parties are not permitted any insight
into the financial affairs. It is therefore difficult to make a proper
assessment of the actual situation.
Financial
Situation: The financial situation
is very good.
Payment
experiences: Payment habits are
considered good.
Business
development: The business trend is
considered as lightly improving.
Maximum
Credit: CHF 15'000'000.--
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.45.11 |
|
|
1 |
Rs.72.91 |
|
Euro |
1 |
Rs.62.56 |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.